SX ANNOUNCEMENT
ADMEDUS CARDIOCEL®
6 YEAR DATA
? CardioCel®
shows no calcification after 6 years
? Extension study continues to show no calcification with CardioCel®
? All patients showing no calcification and no need for follow up surgery
Brisbane, Australia, 28th
April, 2014
Admedus (ASX: AHZ) today announced that 6 years post implantation CardioCel®
continues to show no level of calcification or any other issues.
The first patient from the Phase II study has had their 6 year follow up and the results
show there is still no detectable calcification of CardioCel®
with no “re-do” surgery
required and no other issues. The patient was initially implanted at 3 weeks of age and
has successfully reached their 6
th
birthday with no implant issues.
“This is great progress for patients in not having to have additional surgeries and it
represents huge potential for the future treatment of congenital heart disease and
other cardiac defects” said Admedus CEO Mr Lee Rodne.
All other patients in the study continue to show no signs of calcification or follow up
surgeries after 3 to 5 years. The company anticipates continued data from the ongoing
monitoring of these patients.
“We have always believed that CardioCel®
has enormous potential in the future of
cardiac surgery and this data highlights the longer term benefits of using CardioCel®
and its superiority over alternatives” said Mr Rodne
Patients from the Phase II study are examined for calcification and overall patient
health annually.
Earlier this year Admedus received FDA clearance for CardioCel®
and last year
CardioCel® was approved in Europe under a CE Mark.
- Forums
- ASX - By Stock
- AVR
- admedus cardiocel® 6 year data
admedus cardiocel® 6 year data
-
- There are more pages in this discussion • 53 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.31 |
Change
-0.910(7.45%) |
Mkt cap ! $246.0M |
Open | High | Low | Value | Volume |
$12.20 | $12.22 | $11.21 | $112.6K | 9.596K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 625 | $11.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.45 | 212 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 90 | 11.310 |
2 | 1168 | 11.300 |
1 | 140 | 11.250 |
1 | 107 | 11.240 |
1 | 150 | 11.230 |
Price($) | Vol. | No. |
---|---|---|
11.450 | 212 | 3 |
11.460 | 188 | 2 |
11.470 | 192 | 2 |
11.480 | 150 | 1 |
11.490 | 147 | 1 |
Last trade - 12.12pm 21/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online